I think they’re saying the results can’t be used to determine disease progression and can’t be used as a basis to move to Phase 2. The following sentence says:
”PharmAust intends to continue with MPL dose escalation for Cohorts 3 and 4 to determine the optimum dosage for Phase 2.”
Clearly saying more work needs to be done before moving to Phase 2.
I do think it’s poorly worded for a layman to easily understand.
Ann: Results show MPL suppresses biomarkers associated with MND, page-117
-
- There are more pages in this discussion • 84 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add PAA (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
19.5¢ |
Change
0.000(0.00%) |
Mkt cap ! $86.55M | |||
| Open | High | Low | Value | Volume |
| 19.5¢ | 19.5¢ | 18.5¢ | $330.4K | 1.741M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 4071 | 19.0¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 19.5¢ | 24580 | 3 |
View Market Depth
| Last trade - 16.10pm 28/06/2024 (20 minute delay) ? |
| PAA (ASX) Chart |